421
Participants
Start Date
August 6, 2025
Primary Completion Date
April 30, 2030
Study Completion Date
April 30, 2035
LY4257496
Administered IV
Standard of Care Anticancer Therapies
Fulvestrant, Imlunestrant, Aromatase Inhibitors, Capecitabine, Abemaciclib
NOT_YET_RECRUITING
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
NOT_YET_RECRUITING
Emory University School of Medicine - Winship Cancer Institute, Atlanta
RECRUITING
Biogenix Molecular, LLC, Miami
NOT_YET_RECRUITING
Universitaetsklinikum Essen, Essen
NOT_YET_RECRUITING
Barbara Ann Karmanos Cancer Institute, Detroit
NOT_YET_RECRUITING
BAMF Health Inc., Grand Rapids
NOT_YET_RECRUITING
Washington University, St Louis
NOT_YET_RECRUITING
MD Anderson Cancer Center, Houston
NOT_YET_RECRUITING
University of California, Los Angeles (UCLA), Los Angeles
NOT_YET_RECRUITING
City of Hope, Duarte
RECRUITING
Stanford University Medical Center, Stanford
NOT_YET_RECRUITING
Massachusetts General Hospital, Boston
NOT_YET_RECRUITING
Dana-Farber Cancer Institute, Boston
NOT_YET_RECRUITING
Juravinski Cancer Centre, Hamilton
NOT_YET_RECRUITING
Lady Davis Institute for Medical Research Jewish General Hospital, Montreal
NOT_YET_RECRUITING
Sunnybrook Health Sciences Centre, Toronto
NOT_YET_RECRUITING
Princess Margaret Hospital, Toronto
Eli Lilly and Company
INDUSTRY